58 results on '"McGinty T."'
Search Results
2. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021
- Author
-
Funk T., Pharris A., Spiteri G., Bundle N., Melidou A., Carr M., Gonzalez G., Garcia-Leon A., Crispie F., O'Connor L., Murphy N., Mossong J., Vergison A., Wienecke-Baldacchino A. K., Abdelrahman T., Riccardo F., Stefanelli P., Di Martino A., Bella A., Lo Presti A., Casaca P., Moreno J., Borges V., Isidro J., Ferreira R., Gomes J. P., Dotsenko L., Suija H., Epstein J., Sadikova O., Sepp H., Ikonen N., Savolainen-Kopra C., Blomqvist S., Mottonen T., Helve O., Gomes-Dias J., Adlhoch C., Macori G., Russell L., Yandle Z., Bennett C., O'Byrne E., Murphy A., Tuite G., Conroy A., Duffy M., Morley U., Keoghan B., Ford I., Kennedy M., McDonnell S., Flynn A., Clarke A., Crowley A., Martin C., Kelly E., Foxton J., Hare D., Dunford L., Connell J., Moran J., Dean J., Fanning S., Rajan L., De Gascun C., Kenny J., Cotter P., Walsh C., Lawton E., Fitzpatrick A., Mullins E., Della Bartola M., McCabe M., Stapleton P., Meaney C., Fanning L., Prentice M., MacSharry J., Dempsey C., Mallon P., Leon A., Chaturvedi A., Coughlan S., McAndrew G., Reddington K., Walsh F., Fitzpatrick D., Smyth C., O'Dwyer T., Chambers T., Clarke L., Jebb D., Klopp J., Kavanagh D., Haslam K., Buckley P., Lemass K., Fitzpatrick F., Burns K., Cafferkey J., Richmond A., Foley M., Sanchez-Morgado J., Chalapati S., Pinnamaneni N., Crosbie C., Limbachiya D., Tinago W., Garcia Leon A. A., Miles S., Alalwan D., Negi R., Macken A., Feeney E., Kenny G., McCann K., Kelly N., Blair M., McCann R., Kenny C., O'Brion C., Waqas S., Savinelli S., Doran P., Bracken T., Varghese P., Lambert J. S., Cotter A., Muldoon E., Sheehan G., McGinty T., Lambert J., Green S., Leamy K., de Barra E., McConkey S., Kelly C., Horgan M., Sadlier C., Yousif O., O'Donnell J., Fitzgerald M., Petty-Saphon N., Cuddihy J., Fiore S., Fabiani C., Benedetti E., Di Mario G., Facchini M., Puzelli S., Calzoletti L., Fontana S., Venturi G., Fortuna C., Marsili G., Amendola A., Stuppia L., Savini G., Picerno A., Lopizzo T., Dell'Edera D., Minchella P., Greco F., Mauro M. V., Viglietto G., Atripaldi L., Limone A., D'Agaro P., Licastro D., Marcello A., Capobianchi M. R., Icardi G., Bruzzone B., Lillo F., Orsi A., Pariani E., Baldanti F., Gismondo M. R., Maggi F., Caruso A., Ceriotti F., Boniotti B., Bagnarelli P., Garofalo S., Scutella M., Pagani E., Collini L., Ghisetti V., Ru G., Chironna M., Parisi A., Rubino S., Serra C., Piras G., Coghe F., Vitale F., Tramuto F., Scalia G., Palermo C. I., Mancuso G., Di Gaudio F., Vullo S., Reale S., Cusi M. G., Rossolini G. M., Pistello M., Mencacci A., Camilloni B., Severini S., Di Benedetto M., Calogero T., Monne I., Biscaro V., COVID Study Groups, Funk T., Pharris A., Spiteri G., Bundle N., Melidou A., Carr M., Gonzalez G., Garcia-Leon A., Crispie F., O'Connor L., Murphy N., Mossong J., Vergison A., Wienecke-Baldacchino A.K., Abdelrahman T., Riccardo F., Stefanelli P., Di Martino A., Bella A., Lo Presti A., Casaca P., Moreno J., Borges V., Isidro J., Ferreira R., Gomes J.P., Dotsenko L., Suija H., Epstein J., Sadikova O., Sepp H., Ikonen N., Savolainen-Kopra C., Blomqvist S., Mottonen T., Helve O., Gomes-Dias J., Adlhoch C., Macori G., Russell L., Yandle Z., Bennett C., O'Byrne E., Murphy A., Tuite G., Conroy A., Duffy M., Morley U., Keoghan B., Ford I., Kennedy M., McDonnell S., Flynn A., Clarke A., Crowley A., Martin C., Kelly E., Foxton J., Hare D., Dunford L., Connell J., Moran J., Dean J., Fanning S., Rajan L., De Gascun C., Kenny J., Cotter P., Walsh C., Lawton E., Fitzpatrick A., Mullins E., Della Bartola M., McCabe M., Stapleton P., Meaney C., Fanning L., Prentice M., MacSharry J., Dempsey C., Mallon P., Leon A., Chaturvedi A., Coughlan S., McAndrew G., Reddington K., Walsh F., Fitzpatrick D., Smyth C., O'Dwyer T., Chambers T., Clarke L., Jebb D., Klopp J., Kavanagh D., Haslam K., Buckley P., Lemass K., Fitzpatrick F., Burns K., Cafferkey J., Richmond A., Foley M., Sanchez-Morgado J., Chalapati S., Pinnamaneni N., Crosbie C., Limbachiya D., Tinago W., Garcia Leon A.A., Miles S., Alalwan D., Negi R., Macken A., Feeney E., Kenny G., McCann K., Kelly N., Blair M., McCann R., Kenny C., O'Brion C., Waqas S., Savinelli S., Doran P., Bracken T., Varghese P., Lambert J.S., Cotter A., Muldoon E., Sheehan G., McGinty T., Lambert J., Green S., Leamy K., de Barra E., McConkey S., Kelly C., Horgan M., Sadlier C., Yousif O., O'Donnell J., Fitzgerald M., Petty-Saphon N., Cuddihy J., Fiore S., Fabiani C., Benedetti E., Di Mario G., Facchini M., Puzelli S., Calzoletti L., Fontana S., Venturi G., Fortuna C., Marsili G., Amendola A., Stuppia L., Savini G., Picerno A., Lopizzo T., Dell'Edera D., Minchella P., Greco F., Mauro M.V., Viglietto G., Atripaldi L., Limone A., D'Agaro P., Licastro D., Marcello A., Capobianchi M.R., Icardi G., Bruzzone B., Lillo F., Orsi A., Pariani E., Baldanti F., Gismondo M.R., Maggi F., Caruso A., Ceriotti F., Boniotti B., Bagnarelli P., Garofalo S., Scutella M., Pagani E., Collini L., Ghisetti V., Ru G., Chironna M., Parisi A., Rubino S., Serra C., Piras G., Coghe F., Vitale F., Tramuto F., Scalia G., Palermo C.I., Mancuso G., Di Gaudio F., Vullo S., Reale S., Cusi M.G., Rossolini G.M., Pistello M., Mencacci A., Camilloni B., Severini S., Di Benedetto M., Calogero T., Monne I., Biscaro V., and COVID Study Groups
- Subjects
Infecções Respiratórias ,2019-20 coronavirus outbreak ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Critical Care ,Epidemiology ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,variants of concern ,Settore MED/42 - Igiene Generale E Applicata ,03 medical and health sciences ,0302 clinical medicine ,Virology ,Internal medicine ,Medicine ,Humans ,Intensive care admission ,030212 general & internal medicine ,COVID-19 ,Europe ,SARS-CoV-2 ,surveillance ,Surveillance ,business.industry ,030503 health policy & services ,Public Health, Environmental and Occupational Health ,Odds ratio ,Confidence interval ,Variants of Concern ,COVID-19, Europe, SARS-CoV-2, surveillance, variants of concern ,0305 other medical science ,business ,Rapid Communication ,Human - Abstract
COVID study groups - PORTUGAL: Portuguese Laboratory Network for the Diagnosis of COVID-19 and Public Health Department of the Health Administrative Regions, Physicians that provided data and samples from suspected cases and SARS-CoV-2 genetic characterization. INSA laboratory team for the diagnosis of SARS-CoV-2. Algarve Biomedical Center and Unilabs. We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant cases reported by seven European countries. COVID-19 cases with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0-2.9; B.1.351: 3.6, 95% CI: 2.1-6.2; P.1: 2.6, 95% CI: 1.4-4.8) and B.1.1.7/SGTF and P.1 cases also for intensive care admission (B.1.1.7/SGTF: 2.3, 95% CI: 1.4-3.5; P.1: 2.2, 95% CI: 1.7-2.8). ECDC internal funds. The ICSC and the AIID Cohort are supported by Science Foundation Ireland under the Science Foundation Ireland, Enterprise Ireland, IDA Ireland COVID-19 Rapid Response Funding Call (Grant number: COVID-RRC 20/COV/0103 and COVID-RRC 20/COV/0305). info:eu-repo/semantics/publishedVersion
- Published
- 2021
3. Dynamic Change and Clinical Relevance of Postinfectious SARS-CoV-2 Antibody Responses
- Author
-
Mallon, Patrick W G, Tinago, Willard, Leon, Alejandro Garcia, McCann, Kathleen, Kenny, Grace, McGettrick, Padraig, Green, Sandra, Inzitari, Rosanna, Cottere, Aoife G, Feeney, Eoin R, Savinelli, Stefano, Doran, Peter, Gavin, P, Eustace, J, Horgan, M, Sadlier, C, Lambert, J, McGinty, T, Low, J, Whelan, B, McNicholas, B, Yousif, O, Courtney, G, DeBarra, E, Kelly, C, and Bracken, T
- Subjects
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Immunoglobulin G ,Serology ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,law ,Major Article ,Medicine ,Clinical significance ,030212 general & internal medicine ,Prospective cohort study ,Antibody ,Polymerase chain reaction ,030304 developmental biology ,0303 health sciences ,biology ,SARS-CoV-2 ,business.industry ,COVID-19 ,3. Good health ,AcademicSubjects/MED00290 ,Infectious Diseases ,Oncology ,Immunoglobulin M ,Immunology ,biology.protein ,business - Abstract
Background Although reports suggest that most individuals with coronavirus disease 2019 (COVID-19) develop detectable antibodies postinfection, the kinetics, durability, and relative differences between immunoglobulin M (IgM) and immunoglobulin G (IgG) responses beyond the first few weeks after symptom onset remain poorly understood. Methods Within a large, well-phenotyped, diverse, prospective cohort of subjects with and without severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR)–confirmed infection and historical controls derived from cohorts with high prevalence of viral coinfections and samples taken during prior flu seasons, we measured SARS-CoV-2 serological responses (both IgG and IgM) using commercially available assays. We calculated sensitivity, specificity, and relationship with disease severity and mapped the kinetics of antibody responses over time using generalized additive models. Results We analyzed 1001 samples from 752 subjects, 327 with confirmed SARS-CoV-2 (29.7% with severe disease) spanning a period of 90 days from symptom onset. Sensitivity was lower (44.1%–47.1%) early (80% after 10 days. IgM positivity increased earlier than IgG-targeted assays, but positivity peaked between days 32 and 38 post–onset of symptoms and declined thereafter, a dynamic that was confirmed when antibody levels were analyzed, with a more rapid decline observed with IgM. Early ( Conclusions This study suggests that postinfectious antibody responses in those with confirmed COVID-19 begin to decline relatively early postinfection and suggests a potential role for higher IgM levels early in infection in the prediction of subsequent disease severity.
- Published
- 2021
- Full Text
- View/download PDF
4. 484 CHANGING PRACTICES OF DECISION MAKING REGARDING DO-NOT-ATTEMPT-CARDIOPULMONARY-RESUSCITATION ORDERS AMID THE COVID-19 PANDEMIC
- Author
-
Connellan, D, primary, Diffley, K, additional, McCabe, J, additional, Cotter, A, additional, McGinty, T, additional, Sheehan, G, additional, Ryan, K, additional, Cullen, W, additional, Lambert, J, additional, Callaly, E, additional, and Kyne, L, additional
- Published
- 2021
- Full Text
- View/download PDF
5. New land and marine Tertiary shells from southern Florida
- Author
-
Mcginty, T L and BioStor
- Published
- 1940
6. Oxystyla from western Mexico
- Author
-
Mcginty, T L and BioStor
- Published
- 1939
7. Some new and interesting marine shells from northwest Florida
- Author
-
Schwengel, J S, Mcginty, T L, and BioStor
- Published
- 1942
8. The genus Cyphoma in Florida
- Author
-
Pilsbry, H A, Mcginty, T L, and BioStor
- Published
- 1939
9. Small Cassididae of Florida and the West Indies
- Author
-
Pilsbry, H A, Mcginty, T L, and BioStor
- Published
- 1939
10. Review of Florida Chamidae
- Author
-
Pilsbry, H A, Mcginty, T, and BioStor
- Published
- 1938
11. New marine shells dredged off Palm Beach, Florida
- Author
-
Mcginty, T L and BioStor
- Published
- 1940
12. Collecting on a coral reef in Florida
- Author
-
Mcginty, T L and BioStor
- Published
- 1939
13. Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons
- Author
-
Rotger, M, Glass, Tr, Junier, T, Lundgren, J, Neaton, Jd, Poloni, Es, van 't Wout AB, Lubomirov, R, Colombo, S, Martinez, R, Rauch, A, Günthard, Hf, Neuhaus, J, Wentworth, D, van Manen, D, Gras, La, Schuitemaker, H, Albini, L, Torti, C, Jacobson, Lp, Li, X, Kingsley, La, Carli, F, Guaraldi, G, Ford, Es, Sereti, I, Hadigan, C, Martinez, E, Arnedo, M, Egaña-Gorroño, L, Gatell, Jm, Law, M, Bendall, C, Petoumenos, K, Rockstroh, J, Wasmuth, Jc, Kabamba, K, Delforge, M, De Wit, S, Berger, F, Mauss, S, de Paz Sierra, M, Losso, M, Belloso, Wh, Leyes, M, Campins, A, Mondi, A, De Luca, A, Bernardino, I, Barriuso-Iglesias, M, Torrecilla-Rodriguez, A, Gonzalez-Garcia, J, Arribas, Jr, Fanti, I, Gel, S, Puig, J, Negredo, E, Gutierrez, M, Domingo, P, Fischer, J, Fätkenheuer, G, Alonso-Villaverde, C, Macken, A, Woo, J, Mcginty, T, Mallon, P, Mangili, A, Skinner, S, Wanke, Ca, Reiss, P, Weber, R, Bucher, Hc, Fellay, J, Telenti, A, Tarr, Pe, Vullo, V, Magnificent, Consortium, Insight, Swiss HIV Cohort Study, Mastroianni, C, MAGNIFICENT Consortium, Swiss HIV Cohort Study, INSIGHT, Rotger, M., Glass, TR., Lubomirov, R., Bucher, HC., Telenti, A., Tarr, PE., Junier, T., Poloni, ES., Fellay, J., Colombo, S., Martinez, R., Rauch, A., Weber, R., Günthard, HF., Neuhaus, J., Wentworth, D., Lundgren, J., Neaton, JD., van Manen, D., Gras, AL., Schuitemaker, H., van Wout AB., Reiss, P., Albini, L., Torti, C., Jacobson, LP., Li, X., Kingsley, LA., Carli, F., Guaraldi, G., Ford, ES., Sereti, I., Hadigan, C., Martinez, E., Arnedo-Valero, M., Egaña-Gorroño, L., Gatell, JM., Law, M., Bendall, C., Petoumenos, K., Rockstroh, J., Wasmuth, JC., Kabamba, K., Delforge, M., De Wit, S., Berger, F., Mauss, S., Sierra Mde, P., Losso, M., Belloso, WH., Leyes, M., Campins, A., Mondi, A., De Luca, A., Bernardino, I., Barriuso-Iglesias£££Mónica£££ M., Rodriguez, AT., Garcia, JG., Arribas, JR., Fanti, I., Gel, S., Puig, J., Negredo, E., Gutierrez, M., Domingo, P., Fischer, J., Fätkenheuer, G., Alonso-Villaverde, C., Macken, A., Woo, J., McGinty, T., Mallon, P., Mangili, A., Skinner, S., Wanke, CA., Aubert, V., Barth, J., Battegay, M., Bernasconi, E., Böni, J., Burton-Jeangros, C., Calmy, A., Cavassini, M., Egger, M., Elzi, L., Fehr, J., Francioli, P., Furrer, H., Fux, CA., Gorgievski, M., Günthard, H., Haerry, D., Hasse, B., Hirsch, HH., Hirschel, B., Hösli, I., Kahlert, C., Kaiser, L., Keiser, O., Kind, C., Klimkait, T., Kovari, H., Ledergerber, B., Martinetti, G., Martinez de Tejada, B., Metzner, K., Müller, N., Nadal, D., Pantaleo, G., Regenass, S., Rickenbach, M., Rudin, C., Schmid, P., Schultze, D., Schöni-Affolter, F., Schüpbach, J., Speck, R., Taffé, P., Tarr, P., Trkola, A., Vernazza, P., Prins, YS., Kuijpers, TW., Scherpbier, HJ., Boer, K., van der Meer JT., Wit, FW., Godfried, MH., van der Poll, T., Nellen, FJ., Lange, JM., Geerlings, SE., van Vugt, M., Vrouenraets, SM., Pajkrt, D., Bos, JC., van der Valk, M., Schreij, G., Lowe, S., Lashof, AO., Pronk, MJ., Bravenboer, B., van der Ende ME., de Vries-Sluijs TE., Schurink, CA., van der Feltz, M., Nouwen, JL., Gelinck, LB., Verbon, A., Rijnders, BJ., van de Ven-de Ruiter ED., Slobbe, L., Haag, D., Kauffmann, RH., Schippers, EF., Groeneveld, PH., Alleman, MA., Bouwhuis, JW., ten Kate RW., Soetekouw, R., Kroon, FP., van den Broek PJ., van Dissel JT., Arend, SM., van Nieuwkoop, C., de Boer MJ., Jolink, H., den Hollander JG., Pogany, K., Bronsveld, W., Kortmann, W., van Twillert, G., van Houte DP., Polée, MB., van Vonderen MG., ten Napel CH., Kootstra, GJ., Brinkman, K., Blok, WL., Frissen, PH., Schouten, WE., van den Berk GE., Juttmann, JR., van Kasteren ME., Brouwer, AE., Mulder, JW., van Gorp EC., Smit, PM., Weijer, S., van Eeden, A., Verhagen, DW., Sprenger, HG., Doedens, R., Scholvinck, EH., van Assen, S., Stek, CJ., Hoepelman, IM., Mudrikova, T., Schneider, MM., Jaspers, CA., Ellerbroek, PM., Peters, EJ., Maarschalk-Ellerbroek, LJ., Oosterheert, JJ., Arends, JE., Wassenberg, MW., van der Hilst JC., Richter, C., van der Berg JP., Gisolf, EH., Margolick, JB., Plankey, M., Crain, B., Dobs, A., Farzadegan, H., Gallant, J., Johnson-Hill, L., Sacktor, N., Selnes, O., Shepard, J., Thio, C., Phair, JP., Wolinsky, SM., Badri, S., Conover, C., O'Gorman, M., Ostrow, D., Palella, F., Ragin, A., Detels, R., Martínez-Maza, O., Aronow, A., Bolan, R., Breen, E., Butch, A., Fahey, J., Jamieson, B., Miller, EN., Oishi, J., Vinters, H., Visscher, BR., Wiley, D., Witt, M., Yang, O., Young, S., Zhang, ZF., Rinaldo, CR., Becker, JT., Cranston, RD., Martinson, JJ., Mellors, JW., Silvestre, AJ., Stall, RD., Muñoz, A., Abraham, A., Althoff, K., Cox, C., D'Souza, G., Gange, SJ., Golub, E., Schollenberger, J., Seaberg, EC., Su, S., Huebner, RE., Dominguez, G., Moroni, M., Angarano, G., Antinori, A., Carosi, G., Cauda, R., Monforte£££A d'Arminio£££ A., Di Perri, G., Galli, M., Iardino, R., Ippolito, G., Lazzarin, A., Perno, CF., Sagnelli, E., Viale, PL., Von Schlosser, F., d'Arminio Monforte, A., Ammassari, A., Andreoni, M., Balotta, C., Bonfanti, P., Bonora, S., Borderi, M., Capobianchi, MR., Castagna, A., Ceccherini-Silberstein, F., Cozzi-Lepri, A., Gargiulo, M., Gervasoni, C., Girardi, E., Lichtner, M., Lo Caputo, S., Madeddu, G., Maggiolo, F., Marcotullio, S., Monno, L., Murri, R., Mussini, C., Puoti, M., Formenti, T., Galli, L., Lorenzini, P., Montroni, M., Giacometti, A., Costantini, A., Riva, A., Tirelli, U., Martellotta, F., Ladisa, N., Lazzari, G., Verucchi, G., Castelli, F., Scalzini, A., Minardi, C., Bertelli, D., Quirino, T., Abeli, C., Manconi, PE., Piano, P., Vecchiet, J., Falasca, K., Carnevale, G., Lorenzotti, S., Sighinolfi, L., Segala, D., Leoncini, F., Mazzotta, F., Pozzi, M., Cassola, G., Viscoli, G., Viscoli, A., Piscopo, R., Mazzarello, G., Mastroianni, C., Belvisi, V., Caramma, I., Chiodera, A., Castelli, P., Rizzardini, G., Ridolfo, AL., Foschi, A., Salpietro, S., Galli, A., Bigoloni, A., Spagnuolo, V., Merli, S., Carenzi, L., Moioli, MC., Cicconi, P., Bisio, L., Gori, A., Lapadula, G., Abrescia, N., Chirianni, A., De Marco, M., Ferrari, C., Borghi, R., Baldelli, F., Belfiori, B., Parruti, G., Ursini, T., Magnani, G., Ursitti, MA., Narciso, P., Tozzi, V., Vullo, V., d'Avino, A., Zaccarelli, M., Gallo, L., Acinapura, R., Capozzi, M., Libertone, R., Trotta, MP., Tebano, G., Cattelan, AM., Mura, MS., Caramello, P., Orofino, GC., Sciandra, M., Raise, Ebo, F., Pellizzer, G., Manfrin, V., McManus, H., Wright, S., Moore, R., Edwards, S., Medische Microbiologie, RS: CAPHRI School for Public Health and Primary Care, AII - Amsterdam institute for Infection and Immunity, Experimental Immunology, Other departments, Graduate School, APH - Amsterdam Public Health, Global Health, Medical Microbiology and Infection Prevention, Paediatric Infectious Diseases / Rheumatology / Immunology, Other Research, Obstetrics and Gynaecology, Infectious diseases, General Internal Medicine, Center of Experimental and Molecular Medicine, University of Zurich, Tarr, Philip E, Rotger, M, Glass, T, Junier, T, Lundgren, J, Neaton, J, Poloni, E, Van 'T Wout, A, Lubomirov, R, Colombo, S, Martinez, R, Rauch, A, Günthard, H, Neuhaus, J, Wentworth, D, Van Manen, D, Gras, L, Schuitemaker, H, Albini, L, Torti, C, Jacobson, L, Li, X, Kingsley, L, Carli, F, Guaraldi, G, Ford, E, Sereti, I, Hadigan, C, Martinez, E, Arnedo, M, Egaña Gorroño, L, Gatell, J, Law, M, Bendall, C, Petoumenos, K, Rockstroh, J, Wasmuth, J, Kabamba, K, Delforge, M, De Wit, S, Berger, F, Mauss, S, De Paz Sierra, M, Losso, M, Belloso, W, Leyes, M, Campins, A, Mondi, A, De Luca, A, Bernardino, I, Barriuso Iglesias, M, Torrecilla Rodriguez, A, Gonzalez Garcia, J, Arribas, J, Fanti, I, Gel, S, Puig, J, Negredo, E, Gutierrez, M, Domingo, P, Fischer, J, Fätkenheuer, G, Alonso Villaverde, C, Macken, A, Woo, J, Mcginty, T, Mallon, P, Mangili, A, Skinner, S, Wanke, C, Reiss, P, Weber, R, Bucher, H, Fellay, J, Telenti, A, Tarr, P, Gori, A, Junier, Thomas, Poloni, Estella S., Rotger, Margalida, Glass, Tracy R., Junier, Thoma, Lundgren, Jen, Neaton, James D., Van 't Wout, Angã©lique B., Lubomirov, Rubin, Colombo, Sara, Martinez, Raquel, Rauch, Andri, Gã¼nthard, Huldrych F., Neuhaus, Jacqueline, Wentworth, Deborah, Van Manen, Danielle, Gras, Luuk A., Schuitemaker, Hanneke, Albini, Laura, Torti, Carlo, Jacobson, Lisa P., Li, Xiuhong, Kingsley, Lawrence A., Carli, Federica, Guaraldi, Giovanni, Ford, Emily S., Sereti, Irini, Hadigan, Colleen, Martinez, Esteban, Arnedo, Mireia, Egaã±a gorroã±o, Lander, Gatell, Jose M., Law, Matthew, Bendall, Courtney, Petoumenos, Kathy, Rockstroh, Jã¼rgen, Wasmuth, Jan christian, Kabamba, Kabeya, Delforge, Marc, De Wit, Stephane, Berger, Florian, Mauss, Stefan, De Paz Sierra, Mariana, Losso, Marcelo, Belloso, Waldo H., Leyes, Maria, Campins, Antoni, Mondi, Annalisa, De Luca, Andrea, Bernardino, Ignacio, Barriuso iglesias, Mã³nica, Torrecilla rodriguez, Ana, Gonzalez garcia, Juan, Arribas, Josã© R., Fanti, Iuri, Gel, Silvia, Puig, Jordi, Negredo, Eugenia, Gutierrez, Mar, Domingo, Pere, Fischer, Julia, Fã¤tkenheuer, Gerd, Alonso villaverde, Carlo, Macken, Alan, Woo, Jame, Mcginty, Tara, Mallon, Patrick, Mangili, Alexandra, Skinner, Sally, Wanke, Christine A., Reiss, Peter, Weber, Rainer, Bucher, Heiner C., Fellay, Jacque, Telenti, Amalio, Tarr, Philip E. Swiss Hiv Cohort, and Castagna, Antonella
- Subjects
Male ,HIV Infections ,Genome-wide association study ,030204 cardiovascular system & hematology ,2726 Microbiology (medical) ,10234 Clinic for Infectious Diseases ,Coronary artery disease ,0302 clinical medicine ,ddc:590 ,Risk Factors ,Abacavir ,80 and over ,genetics ,030212 general & internal medicine ,Family history ,Articles and Commentaries ,Aged, 80 and over ,education.field_of_study ,medicine.diagnostic_test ,traditional risk factor ,Single Nucleotide ,Middle Aged ,3. Good health ,Infectious Diseases ,traditional risk factors ,Cohort ,Female ,HIV infection ,antiretroviral therapy ,coronary artery disease ,Human ,medicine.drug ,Adult ,Microbiology (medical) ,medicine.medical_specialty ,Adolescent ,Population ,Infectious Disease ,610 Medicine & health ,Polymorphism, Single Nucleotide ,Genetic Predisposition to Disease ,Aged ,Coronary Artery Disease ,Humans ,Polymorphism ,Young Adult ,03 medical and health sciences ,Internal medicine ,medicine ,education ,Genetic testing ,business.industry ,Risk Factor ,2725 Infectious Diseases ,Odds ratio ,medicine.disease ,Immunology ,genetic ,business - Abstract
BACKGROUND: Persons infected with human immunodeficiency virus (HIV) have increased rates of coronary artery disease (CAD). The relative contribution of genetic background, HIV-related factors, antiretroviral medications, and traditional risk factors to CAD has not been fully evaluated in the setting of HIV infection.METHODS: In the general population, 23 common single-nucleotide polymorphisms (SNPs) were shown to be associated with CAD through genome-wide association analysis. Using the Metabochip, we genotyped 1875 HIV-positive, white individuals enrolled in 24 HIV observational studies, including 571 participants with a first CAD event during the 9-year study period and 1304 controls matched on sex and cohort.RESULTS: A genetic risk score built from 23 CAD-associated SNPs contributed significantly to CAD (P = 2.9 × 10(-4)). In the final multivariable model, participants with an unfavorable genetic background (top genetic score quartile) had a CAD odds ratio (OR) of 1.47 (95% confidence interval [CI], 1.05-2.04). This effect was similar to hypertension (OR = 1.36; 95% CI, 1.06-1.73), hypercholesterolemia (OR = 1.51; 95% CI, 1.16-1.96), diabetes (OR = 1.66; 95% CI, 1.10-2.49), ≥ 1 year lopinavir exposure (OR = 1.36; 95% CI, 1.06-1.73), and current abacavir treatment (OR = 1.56; 95% CI, 1.17-2.07). The effect of the genetic risk score was additive to the effect of nongenetic CAD risk factors, and did not change after adjustment for family history of CAD.CONCLUSIONS: In the setting of HIV infection, the effect of an unfavorable genetic background was similar to traditional CAD risk factors and certain adverse antiretroviral exposures. Genetic testing may provide prognostic information complementary to family history of CAD.
- Published
- 2013
- Full Text
- View/download PDF
14. A new Helicostyla from the Philippine Islands
- Author
-
Mcginty, T L and BioStor
- Published
- 1934
15. A new naticoid snail from Florida
- Author
-
Mcginty, T L and BioStor
- Published
- 1940
16. Terebra flammea Lamarck, a new record for the United States
- Author
-
Mcginty, T L and BioStor
- Published
- 1939
17. COMPARING DEVELOPMENTAL COORDINATION SCREENING SCORES AND POSTURAL SWAY IN CHILDREN AGES SIX TO TWELVE.
- Author
-
Brien, J A, primary, McGinty, T, additional, Gobert, D, additional, and Hunter, D, additional
- Published
- 2001
- Full Text
- View/download PDF
18. Hydatina; vesicaria
- Author
-
McGinty, T., McGinty, T., McGinty, T., and McGinty, T.
- Abstract
http://name.umdl.umich.edu/IC-MOLLUSK1IC-X-202866%5DUMMZ-MOL-202836-202876, https://quod.lib.umich.edu/cgi/i/image/api/thumb/mollusk1ic/202866/UMMZ-MOL-202836-202876/!250,250, The University of Michigan Library provides access to these materials for educational and research purposes. These materials may be under copyright. If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission. If you have questions about the collection, contact the UMMZ Mollusks Division professional staff: mollusk1ic-dlps-help@umich.edu. If you have concerns about the inclusion of an item in this collection, please contact Library Information Technology: libraryit-info@umich.edu.
- Published
- 1946
19. Chama; sinuosa
- Author
-
McGinty, T., McGinty, T., McGinty, T., and McGinty, T.
- Abstract
http://name.umdl.umich.edu/IC-MOLLUSK1IC-X-202795%5DUMMZ-MOL-202795-202835, https://quod.lib.umich.edu/cgi/i/image/api/thumb/mollusk1ic/202795/UMMZ-MOL-202795-202835/!250,250, The University of Michigan Library provides access to these materials for educational and research purposes. These materials may be under copyright. If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission. If you have questions about the collection, contact the UMMZ Mollusks Division professional staff: mollusk1ic-dlps-help@umich.edu. If you have concerns about the inclusion of an item in this collection, please contact Library Information Technology: libraryit-info@umich.edu.
- Published
- 1937
20. Cooperella; atlantica
- Author
-
McGinty, T., McGinty, T., McGinty, T., and McGinty, T.
- Abstract
http://name.umdl.umich.edu/IC-MOLLUSK1IC-X-203379%5DUMMZ-MOL-203369-203409, https://quod.lib.umich.edu/cgi/i/image/api/thumb/mollusk1ic/203379/UMMZ-MOL-203369-203409/!250,250, The University of Michigan Library provides access to these materials for educational and research purposes. These materials may be under copyright. If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission. If you have questions about the collection, contact the UMMZ Mollusks Division professional staff: mollusk1ic-dlps-help@umich.edu. If you have concerns about the inclusion of an item in this collection, please contact Library Information Technology: libraryit-info@umich.edu.
- Published
- 1943
21. Haminoea; glabra
- Author
-
McGinty, T., McGinty, T., McGinty, T., and McGinty, T.
- Abstract
http://name.umdl.umich.edu/IC-MOLLUSK1IC-X-203534%5DUMMZ-MOL-203533-203573, https://quod.lib.umich.edu/cgi/i/image/api/thumb/mollusk1ic/203534/UMMZ-MOL-203533-203573/!250,250, The University of Michigan Library provides access to these materials for educational and research purposes. These materials may be under copyright. If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission. If you have questions about the collection, contact the UMMZ Mollusks Division professional staff: mollusk1ic-dlps-help@umich.edu. If you have concerns about the inclusion of an item in this collection, please contact Library Information Technology: libraryit-info@umich.edu.
22. Olivella; mutica
- Author
-
McGinty, T., McGinty, T., McGinty, T., and McGinty, T.
- Abstract
http://name.umdl.umich.edu/IC-MOLLUSK1IC-X-203807%5DUMMZ-MOL-203807, https://quod.lib.umich.edu/cgi/i/image/api/thumb/mollusk1ic/203807/UMMZ-MOL-203807/!250,250, The University of Michigan Library provides access to these materials for educational and research purposes. These materials may be under copyright. If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission. If you have questions about the collection, contact the UMMZ Mollusks Division professional staff: mollusk1ic-dlps-help@umich.edu. If you have concerns about the inclusion of an item in this collection, please contact Library Information Technology: libraryit-info@umich.edu.
23. Olivella; mutica
- Author
-
McGinty, T., McGinty, T., McGinty, T., and McGinty, T.
- Abstract
http://name.umdl.umich.edu/IC-MOLLUSK1IC-X-203807%5DUMMZ-MOL-203779-203819, https://quod.lib.umich.edu/cgi/i/image/api/thumb/mollusk1ic/203807/UMMZ-MOL-203779-203819/!250,250, The University of Michigan Library provides access to these materials for educational and research purposes. These materials may be under copyright. If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission. If you have questions about the collection, contact the UMMZ Mollusks Division professional staff: mollusk1ic-dlps-help@umich.edu. If you have concerns about the inclusion of an item in this collection, please contact Library Information Technology: libraryit-info@umich.edu.
24. Ringicula; nitida
- Author
-
McGinty, T., McGinty, T., McGinty, T., and McGinty, T.
- Abstract
http://name.umdl.umich.edu/IC-MOLLUSK1IC-X-203895%5DUMMZ-MOL-203861-203901, https://quod.lib.umich.edu/cgi/i/image/api/thumb/mollusk1ic/203895/UMMZ-MOL-203861-203901/!250,250, The University of Michigan Library provides access to these materials for educational and research purposes. These materials may be under copyright. If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission. If you have questions about the collection, contact the UMMZ Mollusks Division professional staff: mollusk1ic-dlps-help@umich.edu. If you have concerns about the inclusion of an item in this collection, please contact Library Information Technology: libraryit-info@umich.edu.
25. Diodora; jaumei
- Author
-
McGinty, T., McGinty, T., McGinty, T., and McGinty, T.
- Abstract
http://name.umdl.umich.edu/IC-MOLLUSK1IC-X-203454%5DUMMZ-MOL-203451-203491, https://quod.lib.umich.edu/cgi/i/image/api/thumb/mollusk1ic/203454/UMMZ-MOL-203451-203491/!250,250, The University of Michigan Library provides access to these materials for educational and research purposes. These materials may be under copyright. If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission. If you have questions about the collection, contact the UMMZ Mollusks Division professional staff: mollusk1ic-dlps-help@umich.edu. If you have concerns about the inclusion of an item in this collection, please contact Library Information Technology: libraryit-info@umich.edu.
26. Cerodrillia; thea
- Author
-
McGinty, T., McGinty, T., McGinty, T., and McGinty, T.
- Abstract
http://name.umdl.umich.edu/IC-MOLLUSK1IC-X-203350%5DUMMZ-MOL-203328-203368, https://quod.lib.umich.edu/cgi/i/image/api/thumb/mollusk1ic/203350/UMMZ-MOL-203328-203368/!250,250, The University of Michigan Library provides access to these materials for educational and research purposes. These materials may be under copyright. If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission. If you have questions about the collection, contact the UMMZ Mollusks Division professional staff: mollusk1ic-dlps-help@umich.edu. If you have concerns about the inclusion of an item in this collection, please contact Library Information Technology: libraryit-info@umich.edu.
27. Papyridea; semisulcata
- Author
-
McGinty, T., McGinty, T., McGinty, T., and McGinty, T.
- Abstract
http://name.umdl.umich.edu/IC-MOLLUSK1IC-X-203049%5DUMMZ-MOL-203041-203081, https://quod.lib.umich.edu/cgi/i/image/api/thumb/mollusk1ic/203049/UMMZ-MOL-203041-203081/!250,250, The University of Michigan Library provides access to these materials for educational and research purposes. These materials may be under copyright. If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission. If you have questions about the collection, contact the UMMZ Mollusks Division professional staff: mollusk1ic-dlps-help@umich.edu. If you have concerns about the inclusion of an item in this collection, please contact Library Information Technology: libraryit-info@umich.edu.
28. Eubela; mcgintyi
- Author
-
McGinty, T., McGinty, T., McGinty, T., and McGinty, T.
- Abstract
http://name.umdl.umich.edu/IC-MOLLUSK1IC-X-203485%5DUMMZ-MOL-203451-203491, https://quod.lib.umich.edu/cgi/i/image/api/thumb/mollusk1ic/203485/UMMZ-MOL-203451-203491/!250,250, The University of Michigan Library provides access to these materials for educational and research purposes. These materials may be under copyright. If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission. If you have questions about the collection, contact the UMMZ Mollusks Division professional staff: mollusk1ic-dlps-help@umich.edu. If you have concerns about the inclusion of an item in this collection, please contact Library Information Technology: libraryit-info@umich.edu.
29. Solemya; occidentalis
- Author
-
McGinty, T., McGinty, T., McGinty, T., and McGinty, T.
- Abstract
http://name.umdl.umich.edu/IC-MOLLUSK1IC-X-203943%5DUMMZ-MOL-203943-203983, https://quod.lib.umich.edu/cgi/i/image/api/thumb/mollusk1ic/203943/UMMZ-MOL-203943-203983/!250,250, The University of Michigan Library provides access to these materials for educational and research purposes. These materials may be under copyright. If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission. If you have questions about the collection, contact the UMMZ Mollusks Division professional staff: mollusk1ic-dlps-help@umich.edu. If you have concerns about the inclusion of an item in this collection, please contact Library Information Technology: libraryit-info@umich.edu.
30. Atlantilux; puella
- Author
-
McGinty, T., McGinty, T., McGinty, T., and McGinty, T.
- Abstract
http://name.umdl.umich.edu/IC-MOLLUSK1IC-X-203677%5DUMMZ-MOL-203656-203696, https://quod.lib.umich.edu/cgi/i/image/api/thumb/mollusk1ic/203677/UMMZ-MOL-203656-203696/!250,250, The University of Michigan Library provides access to these materials for educational and research purposes. These materials may be under copyright. If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission. If you have questions about the collection, contact the UMMZ Mollusks Division professional staff: mollusk1ic-dlps-help@umich.edu. If you have concerns about the inclusion of an item in this collection, please contact Library Information Technology: libraryit-info@umich.edu.
31. Atlantilux; puella
- Author
-
McGinty, T., McGinty, T., McGinty, T., and McGinty, T.
- Abstract
http://name.umdl.umich.edu/IC-MOLLUSK1IC-X-203677%5DUMMZ-MOL-203677, https://quod.lib.umich.edu/cgi/i/image/api/thumb/mollusk1ic/203677/UMMZ-MOL-203677/!250,250, The University of Michigan Library provides access to these materials for educational and research purposes. These materials may be under copyright. If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission. If you have questions about the collection, contact the UMMZ Mollusks Division professional staff: mollusk1ic-dlps-help@umich.edu. If you have concerns about the inclusion of an item in this collection, please contact Library Information Technology: libraryit-info@umich.edu.
32. Making the Home-School Connection: Six Programs that Encourage Educational Computing at Home
- Author
-
McGinty, T.
- Subjects
Educational Software ,Elementary School ,Secondary Schools ,Ppersonal Computers ,Software Quality ,Computer-Assisted Instruction - Published
- 1985
33. What Shakeout? For 85-86, Look for Writing Tools, Textware, Video, and Science
- Author
-
McGinty, T.
- Subjects
Education ,Educational Software ,Trends ,Outlook ,Software ,Computer Software Industry ,Publishing Industry - Published
- 1985
34. Software Preview Special: The Big Sift
- Author
-
Burroughs, R., Reinhold, F., McGinty, T., and Kraner, M.R.
- Subjects
Education ,Computer-Assisted Instruction ,Review ,Educational Software ,Teaching ,Software Packages ,Microcomputer - Published
- 1985
35. Tracking Truants with Automatic Dialers
- Author
-
McGinty, T.
- Subjects
Directories ,Automatic Dialing ,Modem ,Products ,Microcomputer ,Robots ,Education ,Education Administration Software - Published
- 1985
36. NEA Software Approval Still Drawing Criticism
- Author
-
McGinty, T.
- Subjects
Education ,Educational Software ,Computer Software Industry ,Software Quality ,Software Selection ,Evaluation ,Trade and Professional Associations - Published
- 1985
37. West Virginia: A Plan to Link Every School
- Author
-
McGinty, T.
- Subjects
Telecommunications ,Education ,Networks ,West Virginia ,Personal Computers ,Bulletin Board ,Modem ,Secondary Schools ,Cost ,System Selection - Published
- 1984
38. Buying Modems: What to Look For
- Author
-
McGinty, T.
- Subjects
Telecommunications ,Modem ,Directories ,Hardware Selection ,Criteria ,Transmission Speed ,Acoustic Couplers ,Data Communications Software - Published
- 1984
39. Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons
- Author
-
Rotger, M., Glass, T. R., Junier, T., Lundgren, J., Neaton, J. D., Poloni, E. S., Van 'T Wout, A. B., Lubomirov, R., Colombo, S., Martinez, R., Rauch, Andri, Gunthard, H. F., Neuhaus, J., Wentworth, D., Van Manen, D., Gras, L. A., Schuitemaker, H., Albini, L., Torti, C., Jacobson, L. P., Li, X., Kingsley, L. A., Carli, F., Guaraldi, G., Ford, E. S., Sereti, I., Hadigan, C., Martinez, E., Arnedo, M., Egana-Gorrono, L., Gatell, J. M., Law, M., Bendall, C., Petoumenos, K., Rockstroh, J., Wasmuth, J.-C., Kabamba, K., Delforge, M., De Wit, S., Berger, F., Mauss, S., De Paz Sierra, M., Losso, M., Belloso, W. H., Leyes, M., Campins, A., Mondi, A., De Luca, A., Bernardino, I., Barriuso-Iglesias, M., Torrecilla-Rodriguez, A., Gonzalez-Garcia, J., Arribas, J. R., Fanti, I., Gel, S., Puig, J., Negredo, E., Gutierrez, M., Domingo, P., Fischer, J., Fatkenheuer, G., Alonso-Villaverde, C., Macken, A., Woo, J., McGinty, T., Mallon, P., Mangili, A., Skinner, S., Wanke, C. A., Reiss, P., Weber, R., Bucher, H. C., Fellay, J., Telenti, A., and Tarr, P. E.
- Subjects
610 Medicine & health ,3. Good health - Abstract
Background Persons infected with human immunodeficiency virus (HIV) have increased rates of coronary artery disease (CAD). The relative contribution of genetic background, HIV-related factors, antiretroviral medications, and traditional risk factors to CAD has not been fully evaluated in the setting of HIV infection. Methods In the general population, 23 common single-nucleotide polymorphisms (SNPs) were shown to be associated with CAD through genome-wide association analysis. Using the Metabochip, we genotyped 1875 HIV-positive, white individuals enrolled in 24 HIV observational studies, including 571 participants with a first CAD event during the 9-year study period and 1304 controls matched on sex and cohort. Results A genetic risk score built from 23 CAD-associated SNPs contributed significantly to CAD (P = 2.9×10−4). In the final multivariable model, participants with an unfavorable genetic background (top genetic score quartile) had a CAD odds ratio (OR) of 1.47 (95% confidence interval [CI], 1.05–2.04). This effect was similar to hypertension (OR = 1.36; 95% CI, 1.06–1.73), hypercholesterolemia (OR = 1.51; 95% CI, 1.16–1.96), diabetes (OR = 1.66; 95% CI, 1.10–2.49), ≥1 year lopinavir exposure (OR = 1.36; 95% CI, 1.06–1.73), and current abacavir treatment (OR = 1.56; 95% CI, 1.17–2.07). The effect of the genetic risk score was additive to the effect of nongenetic CAD risk factors, and did not change after adjustment for family history of CAD. Conclusions In the setting of HIV infection, the effect of an unfavorable genetic background was similar to traditional CAD risk factors and certain adverse antiretroviral exposures. Genetic testing may provide prognostic information complementary to family history of CAD.
40. Post-COVID care delivery: The experience from an Irish tertiary centre's post-COVID clinic.
- Author
-
Heeney A, Connolly SP, Dillon R, O'Donnell A, McSweeney T, O'Kelly B, Cotter AG, Sheehan G, Lambert JS, Muldoon EG, and McGinty T
- Subjects
- Humans, Female, Adult, Male, SARS-CoV-2, Retrospective Studies, Amber, Cough, COVID-19 epidemiology
- Abstract
Background: The long-term effects of SARS-CoV-2 infection and optimal follow-up approach are not well-recognised. Here we describe the implementation of a post-COVID clinic in an Irish tertiary centre after the first wave of the pandemic. This study describes the characteristics of our patient cohort and the operations and outcomes of the clinic, exploring some of the risk factors for developing post-COVID syndrome and the appropriateness of the triage system employed., Methods: All SARS-CoV-2 positive patients from March 10th to June 14th 2020 were telephone-triaged as red, amber or green based on ongoing symptoms with clinic appointments scheduled accordingly. All clinic visits were face-to-face with the infectious diseases medical team and a proforma for each patient was completed. Data were collected retrospectively by reviewing the proformas and the electronic medical record (EMR)., Results: 311 patients attended the clinic. Median time from illness to clinic appointment was 95 days (IQR 77-105.5). 204 patients (66%) were female, 192 (62%) were hospital staff, and the median age was 43 years (IQR 31-53). 138 patients (44%) had required hospital admission. At their first clinic visit 219 patients (70%) had ongoing symptoms. A further appointment was made for 62 patients (20%). 34 patients (11%) were discussed at an MDT meeting, and 55 (18%) were referred onward to a specialist service. 85% of those triaged green, 73% of those triaged amber, and 39% of those triaged red did not receive further follow up after one clinic visit. Patients were more likely to require follow up with reported dyspnoea (OR 5.6; 95% CI 2.8-11.3; p <0.001), cough (OR 3.0; 95% CI 1.1-8.4, p = 0.04), and palpitations (OR 3.6; 95% CI 1.0-12.3; p = 0.04). Female sex was associated with increased odds of a higher triage category (OR 1.8; 95% CI 1.08 to 3.20; p = 0.02), as was requiring admission to hospital (OR 4.0; 95% CI 2.34 to 6.90; p < 0.001)., Conclusion: The long-term effects of COVID-19 are significant with 70% of our cohort experiencing persistent symptoms. Persistent dyspnoea, cough and palpitations were associated with increased need for follow up. This study also suggests that a traffic light telephone-triage service followed by a face-to-face medical-led clinic could be an effective way of identifying patients who require further management., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2023 Heeney et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2023
- Full Text
- View/download PDF
41. Mixed methods protocol to examine the acceptability and clinical characteristics of a remote monitoring programme for delivery of COVID-19 care, among healthcare staff and patients.
- Author
-
Fox R, Mulcahy Symmons S, De Brún A, Joyce D, Muldoon EG, McGinty T, O'Reilly KMA, O'Connor E, and McAuliffe E
- Subjects
- Cross-Sectional Studies, Delivery of Health Care, Humans, Pandemics, SARS-CoV-2, COVID-19
- Abstract
Introduction: The use of remote monitoring technology to manage the care of patients with COVID-19 has been implemented to help reduce the burden placed on healthcare systems during the pandemic and protect the well-being of both staff and patients. Remote monitoring allows patients to record their signs and symptoms remotely (eg, while self-isolating at home) rather than requiring hospitalisation. Healthcare staff can, therefore, continually monitor their symptoms and be notified when the patient is showing signs of clinical deterioration. However, given the recency of the COVID-19 outbreak, there is a lack of research regarding the acceptance of remote monitoring interventions to manage COVID-19. This study will aim to evaluate the use of remote monitoring for managing COVID-19 cases from the perspective of both the patient and healthcare staff., Methods and Analysis: Discharged patients from a large urban teaching hospital in Ireland, who have undergone remote monitoring for COVID-19, will be recruited to take part in a cross-sectional study consisting of a quantitative survey and a qualitative interview. A mixed methods design will be used to understand the experiences of remote monitoring from the perspective of the patient. Healthcare staff who have been involved in the provision of remote monitoring of patients with COVID-19 will be recruited to take part in a qualitative interview to understand their experiences with the process. Structural equation modelling will be used to examine the acceptance of the remote monitoring technology. Latent class analysis will be used to identify COVID-19 symptom profiles. Interview data will be examined using thematic analysis., Ethics and Dissemination: Ethical approval has been granted by the ethical review boards at University College Dublin and the National Research Ethics Committee for COVID-19-related Research. Findings will be disseminated via publications in scientific journals, policy briefs, short reports and social media., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
42. Rapid and Laboratory SARS-CoV-2 Antibody Testing in High-Risk Hospital Associated Cohorts of Unknown COVID-19 Exposure, a Validation and Epidemiological Study After the First Wave of the Pandemic.
- Author
-
O'Kelly B, McLaughlin R, O'Doherty R, Carroll H, Murray R, Dilworth R, Corkery L, Cotter AG, McGinty T, Muldoon EG, Cullen W, Avramovic G, Sheehan G, Sadlier D, Higgins M, O'Gorman P, Doran P, Inzitari R, Holden S, O'Meara Y, Ennis S, and Lambert JS
- Abstract
Objective: We aimed to use SARS-CoV-2 antibody tests to assess the asymptomatic seroprevalence of individuals in high-risk hospital cohorts who's previous COVID-19 exposure is unknown; staff, and patients requiring haemodialysis or chemotherapy after the first wave. Methods: In a single Center, study participants had five SARS-CoV-2 antibody tests done simultaneously; one rapid diagnostic test (RDT) (Superbio Colloidal Gold IgM/IgG), and four laboratory tests (Roche Elecsys® Anti-SARS-CoV-2 IgG [RE], Abbott Architect i2000SR IgG [AAr], Abbott Alinity IgG [AAl], and Abbott Architect IgM CMIA). To determine seroprevalence, only positive test results on laboratory assay were considered true positives. Results: There were 157 participants, of whom 103 (65.6%) were female with a median age of 50 years (range 19-90). The IgG component of the RDT showed a high number of false positives ( n = 18), was inferior to the laboratory assays ( p < 0.001 RDT vs. AAl/AAr, p < 0.001 RDT vs. RE), and had reduced specificity (85.5% vs. AAl/AAr, 87.2% vs. RE). Sero-concordance was 97.5% between IgG laboratory assays (RE vs. AAl/AAr). Specificity of the IgM component of the RDT compared to Abbott IgM CMIA was 95.4%. Ten participants had positivity in at least one laboratory assay, seven (9.9%) of which were seen in HCWs. Two (4.1%) hematology/oncology (H/O) patients and a single (2.7%) haemodialysis (HD) were asymptomatically seropositive. Asymptomatic seroprevalence of HCWs compared to patients was not significant ( p = 0.105). Conclusion: HCWs (9.9%) had higher, although non-significant asymptomatic seroprevalence of SARS-CoV-2 antibodies compared to high-risk patients (H/O 4.1%, HD 2.7%). An IgM/IgG rapid diagnostic test was inferior to laboratory assays. Sero-concordance of 97.5% was found between IgG laboratory assays, RE vs. AAl/AAr., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 O'Kelly, McLaughlin, O'Doherty, Carroll, Murray, Dilworth, Corkery, Cotter, McGinty, Muldoon, Cullen, Avramovic, Sheehan, Sadlier, Higgins, O'Gorman, Doran, Inzitari, Holden, O'Meara, Ennis and Lambert.)
- Published
- 2021
- Full Text
- View/download PDF
43. Antibiotic prescribing patterns in patients hospitalized with COVID-19: lessons from the first wave.
- Author
-
O'Kelly B, Cronin C, Connellan D, Griffin S, Connolly SP, McGrath J, Cotter AG, McGinty T, Muldoon EG, Sheehan G, Cullen W, Doran P, McHugh T, Vidal L, Avramovic G, and Lambert JS
- Abstract
Background: A high proportion of hospitalized patients with COVID-19 receive antibiotics despite evidence to show low levels of true bacterial coinfection., Methods: A retrospective cohort study examining antibiotic prescribing patterns of 300 patients sequentially diagnosed with COVID-19. Patients were grouped into 3 sub-cohorts: Group 1 received no antibiotics, Group 2 received antibiotics for microbiologically confirmed infections and Group 3 was empirically treated with antibiotics for pneumonia. The primary aim was to identify factors that influenced prescription and continuation of antibiotics in Group 3. Secondary aims were to examine differences in outcomes between groups., Results: In total, 292 patients were included (63 Group 1, 35 Group 2, 194 Group 3), median age was 60 years (IQR 44-76) and the majority were ethnically Irish (62%). The median duration of antibiotics was 7 days (IQR 5-10). In Group 3, factors associated with prescription IV antibiotics on admission were raised C-reactive protein (CRP) ( P = 0.024), increased age ( P = 0.023), higher quick SOFA ( P = 0.016) score and fever >37.5 °C ( P = 0.011). Factors associated with duration of antibiotic course were duration of hypoxia ( P < 0.001) and maximum respiratory support requirement ( P = 0.013). Twenty-one patients in Group 3 had one or more antibiotic escalation events, most ( n = 139) had no escalation or de-escalation of therapy., Conclusions: Duration of hypoxia and need for respiratory support may have acted as surrogate measures of improvement where usual response measures (CRP, neutrophilia, culture clearance) were absent. Continuous review of antibiotic prescriptions should be at the forefront of clinical management of hospitalized patients with COVID-19., (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.)
- Published
- 2021
- Full Text
- View/download PDF
44. Documentation of Do-Not-Attempt-Cardiopulmonary-Resuscitation orders amid the COVID-19 pandemic.
- Author
-
Connellan D, Diffley K, McCabe J, Cotter A, McGinty T, Sheehan G, Ryan K, Cullen W, Lambert JS, Callaly EL, and Kyne L
- Subjects
- Aged, Cross-Sectional Studies, Decision Making, Documentation, Humans, Pandemics, Resuscitation Orders, Retrospective Studies, SARS-CoV-2, COVID-19, Cardiopulmonary Resuscitation
- Abstract
Introduction: the COVID-19 pandemic has brought the decision-making process regarding cardiopulmonary resuscitation (CPR) into focus. The aim of this study is to compare rates of Do-Not-Attempt-CPR (DNACPR) documentation in older hospitalised patients before and during the COVID-19 pandemic., Methods: this was a retrospective repeated cross-sectional study. Data including co-morbidities and resuscitation status was collected on 300 patients with COVID-19 hospitalised from 1 March to 31 May 2020. DNACPR documentation rates in patients aged ≥65 years with a diagnosis of COVID-19 were compared to those without COVID-19 admitted during the same period and were also compared to the documentation rates pre-COVID-19 pandemic (1 March-31 May 2019)., Results: of 300 COVID-19-positive patients, 28% had a DNACPR order documented during their admission. Of 131 older (≥65 years) patients with COVID-19, 60.3% had a DNACPR order compared to 25.4% of 130 older patients without COVID-19 (P < 0.0001). During a comparable time period pre-pandemic, 15.4% of 130 older patients had a DNACPR order in place (P < 0.0001). Almost fifty percent of DNACPR orders were recorded within 24 h of a positive swab result for SARS-CoV-2. Of older COVID-19-positive patients, 39.2% were referred to palliative care services and 70.2% survived., Conclusion: the COVID-19 pandemic has prompted more widespread and earlier decision-making regarding resuscitation status. Although case fatality rates were higher for older hospitalised patients with COVID-19, many older patients survived the illness. Advance care planning should be prioritised in all patients and should remain as part of good clinical practice despite the pandemic., (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
45. Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS-CoV-2.
- Author
-
O'Kelly B, McGettrick P, Angelov D, Fay M, McGinty T, Cotter AG, Sheehan G, and Lambert JS
- Subjects
- Adult, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Bleomycin administration & dosage, COVID-19, Coronavirus Infections diagnosis, Coronavirus Infections drug therapy, Cyclophosphamide administration & dosage, Cytarabine administration & dosage, Dacarbazine administration & dosage, Doxorubicin administration & dosage, Etoposide administration & dosage, Female, Humans, Idarubicin administration & dosage, Pandemics, Pneumonia, Viral diagnosis, Pneumonia, Viral drug therapy, Prednisone administration & dosage, Procarbazine administration & dosage, SARS-CoV-2, Treatment Outcome, Vinblastine administration & dosage, Vincristine administration & dosage, Anti-Bacterial Agents administration & dosage, Antibodies, Monoclonal, Humanized administration & dosage, Betacoronavirus, Hodgkin Disease diagnostic imaging, Hodgkin Disease drug therapy, Hodgkin Disease virology, Hydroxychloroquine administration & dosage, Mediastinal Neoplasms diagnostic imaging, Mediastinal Neoplasms drug therapy, Mediastinal Neoplasms virology, Positron-Emission Tomography
- Published
- 2020
- Full Text
- View/download PDF
46. Assessment of trabecular bone score, an index of bone microarchitecture, in HIV positive and HIV negative persons within the HIV UPBEAT cohort.
- Author
-
McGinty T, Cotter AG, Sabin CA, Macken A, Kavanagh E, Compston J, Sheehan G, Lambert J, and Mallon PWG
- Subjects
- Absorptiometry, Photon, Adult, Cohort Studies, Female, Fractures, Bone etiology, HIV Infections complications, Humans, Lumbar Vertebrae diagnostic imaging, Male, Middle Aged, Prospective Studies, Risk Factors, Smoking adverse effects, Bone Density, Cancellous Bone diagnostic imaging, HIV Infections diagnostic imaging
- Abstract
Introduction: Increased prevalence of low bone mineral density (BMD) and increased fracture incidence are observed in persons living with HIV (PLWH). The trabecular bone score (TBS) is a novel index of bone microarchitecture which improves fracture prediction independent of BMD., Methods: The HIV UPBEAT study is a single centre, prospective cohort study that enrolled subjects with and without HIV from similar sociodemographic backgrounds for annual assessments of bone health. TBS was derived from lumbar spine (LS) dual-energy X-ray absorptiometry images. Univariate and multivariable linear regression was used to assess relationships between baseline TBS, BMD, sociodemographic and clinical factors., Results: 463 subjects (201 HIV positive) were included; PLWH were younger and more likely male, of non-African ethnicity and current smokers. HIV was associated with a mean reduction of 0.037 [-0.060, -0.013] (p = 0.002) in TBS. Lower TBS was also associated with male gender, non-African ethnicity, current smoking status and lower LS BMD. HIV remained associated with lower TBS after adjustment for LS BMD, age, gender and ethnicity. However, adjustment for current smoking significantly attenuated the association between HIV and TBS, with further adjustment for higher bone turnover markers largely explaining any residual association. Among the sub-group of PLWH, exposure to protease inhibitors and lower nadir CD4+ T-cell counts were both predictors of lower TBS., Conclusions: PLWH have lower TBS independent of LS BMD. However, this is largely explained by higher current smoking rates and higher bone turnover in those with HIV. Exposure to PI, but not tenofovir disproxil fumarate, also contributed to lower TBS in those with HIV., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2019
- Full Text
- View/download PDF
47. Fractures and the gut microbiome.
- Author
-
McGinty T and Mallon PWG
- Subjects
- Animals, Disease Models, Animal, HIV Infections complications, Humans, Mice, Bacterial Translocation immunology, Bone Resorption complications, Bone Resorption etiology, Dysbiosis complications, Fractures, Bone epidemiology, Fractures, Bone etiology, Gastrointestinal Microbiome
- Abstract
Purpose of Review: The role of the gut microbiome in the pathogenesis of several inflammatory, non-AIDS comorbidities, such as cardiovascular disease, cognitive impairment and liver disease has become a focus of recent research. Low bone mineral density (BMD) and increased fracture incidence in people living with HIV (PLWH) is also widely reported, however, the relationship between alterations in the gut microbiome and bone disease in PLWH has not been previously reviewed., Recent Findings: Murine models that manipulate the gut microbiome, either through breeding of 'germ-free' mice or antibiotic-depleted gut microbiome, show differences in bone mineral density and bone mass in those with altered gut microbiome. This effect is reported to be driven via changes in the gut-immune-skeletal axis, with changes favouring bone resorption. Several inflammatory conditions wherever bone loss is a prominent feature, such as rheumatoid arthritis and inflammatory bowel disease, have also reported alterations in the gut microbiome, which are associated with bone loss, again through changes in the gut-immune-skeletal axis., Summary: The interplay between the gut microbiome and the immune-skeletal axis in HIV represents a complex relationship. Alterations in the gut microbiome, which induce an activated immune phenotype and inflammatory milieu are associated with non-AIDS comorbidities in PLWH and bone loss in several other conditions characterized by chronic immune activation and inflammation. It is, therefore, likely that there are comparable effects between altered gut microbiome and bone loss in HIV, however, further research is required to better define this relationship in populations of PLWH.
- Published
- 2018
- Full Text
- View/download PDF
48. The role of physical therapy and rehabilitation after lumbar fusion surgery for degenerative disease: a systematic review.
- Author
-
Madera M, Brady J, Deily S, McGinty T, Moroz L, Singh D, Tipton G, and Truumees E
- Subjects
- Humans, Intervertebral Disc Degeneration rehabilitation, Intervertebral Disc Degeneration surgery, Lumbar Vertebrae surgery, Physical Therapy Modalities, Spinal Fusion
- Abstract
OBJECTIVE The purpose of this study was to provide a systematic and comprehensive review of the existing literature regarding postfusion rehabilitation. METHODS Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, the authors conducted an exhaustive review of multiple electronic databases. Potential articles were screened using inclusion/exclusion criteria. Two authors independently analyzed these studies using predefined data fields, including study quality indicators such as level of evidence and availability of accepted patient-reported outcomes measures. These findings were synthesized in a narrative format. A third author resolved disagreements regarding the inclusion of a study. RESULTS Twenty-one articles with I or II levels of evidence were included in the review. The authors divided the findings of the literature review into several groups: rehabilitation terminology, timing and duration of postfusion rehabilitation, the need for rehabilitation relative to surgery-related morbidity, rehabilitation's relationship to outcomes, and cognitive and psychosocial aspects of postsurgical rehabilitation. Current evidence generally supports formal rehabilitation after lumbar fusion surgery. Starting physical therapy at the 12-week postoperative mark results in better outcomes at lower cost than an earlier, 6-week start. Where available, psychosocial support improves outcomes. However, a number of the questions could not be answered with high-grade evidence. In these cases, the authors used "best evidence available" to make recommendations. There are many cases in which different types of caregivers use clinical terminology differently. The data supporting an optimal protocol for postfusion rehabilitation remains elusive but, using the data available, the authors have crafted recommendations and a model protocol, which is currently undergoing prospective study. CONCLUSIONS Rehabilitation has long been a common feature in the postoperative management of patients undergoing spinal fusion. Although caregivers from multiple disciplines agree that the majority of their patients will benefit from this effort, the supporting data remain sparse. In creating a model protocol for postlumbar fusion rehabilitation, the authors hope to share a starting point for future postoperative lumbar fusion rehabilitation research.
- Published
- 2017
- Full Text
- View/download PDF
49. Protecting bone in long-term HIV positive patients receiving antiretrovirals.
- Author
-
McGinty T and Mallon P
- Subjects
- Absorptiometry, Photon, Anti-Retroviral Agents administration & dosage, Anti-Retroviral Agents adverse effects, Bone Density Conservation Agents administration & dosage, Bone Density Conservation Agents therapeutic use, Cholecalciferol administration & dosage, Cholecalciferol therapeutic use, Ergocalciferols administration & dosage, Ergocalciferols therapeutic use, Fractures, Bone complications, Fractures, Bone epidemiology, HIV Infections complications, HIV Infections epidemiology, Humans, Osteoporosis complications, Osteoporosis epidemiology, Risk Factors, Anti-Retroviral Agents therapeutic use, Bone Density drug effects, Fractures, Bone prevention & control, HIV Infections drug therapy, Osteoporosis prevention & control
- Abstract
Introduction: As the population of people living with HIV ages, the increase in non-AIDs morbidities is expected to increase in parallel. Maintaining bone health in those with HIV will be an important area of focus for the HIV clinician to prevent the morbidity and mortality associated with fragility fractures, the principal clinical sequela of low bone mineral density (BMD). Rates of fractures and prevalence of low bone mineral density, a risk factor for future fragility fractures, are already increased in the HIV positive population., Areas Covered: This review examines the strategies to maintain bone health in those living with HIV from screening through to managing those with established low BMD or fracture, including the role for choice of or modification of antiretroviral therapy to maintain bone health. Expert commentary: The increasing complexity of managing bone health in the age of succesful antiretroviral therapy and an aging patient population as well as future perspectives which may help achieve the long term aim of minimising the impact of low BMD in those with HIV are discussed and explored.
- Published
- 2016
- Full Text
- View/download PDF
50. Does systemic inflammation and immune activation contribute to fracture risk in HIV?
- Author
-
McGinty T, Mirmonsef P, Mallon PW, and Landay AL
- Subjects
- Bone Resorption, Humans, Osteogenesis, Risk Assessment, Fractures, Bone etiology, HIV Infections complications, HIV Infections pathology, Inflammation complications, Inflammation pathology, Osteoporosis complications
- Abstract
Purpose of Review: There is increasing evidence pointing toward an important role of heightened immune activation and inflammation in people living with HIV contributing to the development of non-AIDS comorbidities. This review aims to explore low bone mineral density (BMD) in HIV with a focus on the underlying mechanisms and relationships between the immune and skeletal systems., Recent Findings: Baseline immune activation and inflammation negatively impact BMD at antiretroviral therapy (ART) initiation. B- and T-cell alterations in HIV lead to an imbalance in the osteoblastic osteoprotegerin (OPG) and osteoclastic receptor activator of NF-κB ligand (RANKL) cytokines which favours osteoclastogenesis and bone resorption. These findings suggest an important role for immune-mediated mechanisms in the pathogenesis of low BMD in HIV., Summary: Bone homeostasis is in part regulated by cells of the immune system through complex interactions with the RANK/RANKL/OPG axis. Disturbances in the normal functioning of T, B cells, and monocytes in HIV and the resulting proinflammatory state may contribute to dysregulation of this finely controlled balance leading to increased bone loss. Pre-ART levels of immune activation and inflammation have a consistently negative effect on BMD and further suggest the immunocentric basis of bone loss in HIV alongside supporting the benefits of earlier ART initiation. Further longitudinal studies will help determine the effect this will have on fracture risk in people living with HIV.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.